•1-Acid Glycoprotein in Late-Life Depression: Relationship to Medical Burden and Genetics

Abstract

Serum •1-acid glycoprotein (AAG) concentrations were examined in relationship to age, medical burden, depression, and mental status in elderly control (n = 19, mean age = 72.1 ± 6.8 years) and depressed (n = 58, mean age = 71.9 ± 7.1 years) subjects. DNA was analyzed for allelic variants of the AGP1 (ORM1) gene in both groups. Depressed subjects’ AAG serum levels were measured at baseline and after 6 weeks of antidepressant treatment. Before treatment, depressed subjects had significantly higher serum AAG concentrations than nondepressed controls (t49.2 = –3.48, P= .0011). Pretreatment AAG levels also correlated with degree of medical burden, measured by the Cumulative Illness Rating Scale–Geriatrics (r= 0.28, P= .0303), but not with age, depression severity, or cognitive scores. There was no significant difference between responders and nonresponders on changes in AAG levels from baseline to week 6. Frequency differences in ORM1 allelic variants apparently did not influence increased AAG concentrations in depressed patients.

Get full access to this article

View all access options for this article.

References

1. Kremer JMH, Wilting J, Janssen LHM. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40:1-47.

2. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metabol Rev 2001; 33(2):161-235.

3. Fournier T, Medjoubi NN, Porquet D. Alpha-1-acid glycoprotein. Biochimica Biophysica Acta2000; 1482:157-171.

4. Nemeroff CB, Krisnan RR, Blazer DG, et al. Elevated plasma concentrations of alpha-1-acid glycoprotein, a putative endogenous inhibitor of the tritiated imipramine binding site, in depressed patients. Arch Gen Psychiatry 1990; 47:337-340.

5. Healy D, Calvin J, Whitehouse AM, et al. Alpha-1-acid glycoprotein in major depressive and eating disorders. J Affect Disord 1991; 22:13-20.

6. Henry OF, Blacher J, Verdavaine J, et al. Alpha 1-acid glycoprotein is an independent predictor of in-hospital death in the elderly. Age Ageing 2003; 32:37-42.

7. Kehoe WA, Kwentus JA, Sheffel WB, Harralson AF. Increased alpha-1-acid glycoprotein in depression lowers free fraction of imipramine. Biol Psychiatry 1991; 29:489-493.

8. Nieto E, Vieta E, Alvarez L, et al. Alpha-1-acid glycoprotein in major depressive disorder: relationships to severity, response to treatment and imipramine plasma levels. J Affect Disord 2000; 59:159-164.

9. Young RC, Patel A, Meyers BS, et al. Alpha-1-acid glycoprotein, age, and sex in mood disorders. Am J Geriatr Psychiatry 1999; 7(4):331-334.

10.

10. Blain PG, Mucklow JC, Rawlins MD, et al. Determinants of plasma alpha-1-acid glycoprotein concentrations in health [abstract]. Br J Clin Pharmacol 1981; 12:275-275.

11.

11. Abernathy DR, Kerzner L. Age effects on alpha-1-acid glycoprotein concentration and imipramine plasma protein binding. J Am Geriatr Soc 1984; 32:705-708.

12.

12. Yuasa I, Umetsu K, Suenaga K, Robinet-Levy M. Orosomucoid (ORM) typing by isoelectric focusing: evidence for two structural loci ORM1 and ORM2. Hum Genet 1986; 74:160-161.

13.

13. Yuasa I, Umetsu K, Vogt U, et al. Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S. Hum Genet 1997; 99:393-398.

14.

14. Folstein MF, Folstein SE, McHigh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.

15.

15. Mulsant BH, Pollock BG, Nebes R, et al. A double-blind, randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: six-week outcome. J Clin Psychiatry 1999; 60:16-20.

16.

16. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999; 60:9-15.